Cell and gene therapies (C>s) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C>s are continuing to expand, there is a widening gap between the potential of treatment advances and the patient experience. The industry is beginning to acknowledge the problems faced in one of healthcare’s most complex areas for patient experience, according to EmerGENE’s Nareda Mills (Global President Patient Solutions) and Ben Beckley (Global Lead).
For both patients and their healthcare providers (HCPs), the requirement that prior authorizations (PAs) be obtained from health insurers for many branded and specialty medications continues to act as a significant roadblock, according to David Fidler, senior director product innovation at ConnectiveRx.
Do you still have your Marketing 101 textbook? If it devotes a chapter to the “Four Ps of Marketing,” it’s time to throw it out. There is a whole new P-centric marketing mix that is poised to shake up the marketing landscape.
Ashfield Engage, part of UDG Healthcare plc., announced the completion of the acquisition of Nuvera LLC, a U.S.-based healthcare consulting firm specializing in patient support programs. Nuvera’s expertise in optimizing the design and build of seamless patient and HCP treatment experiences will enhance Ashfield Engage’s Patient Solutions capabilities and create an end-to-end strategic offering across their client’s product lifecycles.
As the U.S. moves from managing COVID-19 to managing a recovery, it is clear that the pandemic lockdowns had a profound impact on how people consume media, how they receive healthcare information, and their expectations changed around how brands connect with them. For marketers, building brand value with customers will be tantamount to marketing success in this brave new world.
As we continue to sift through the barrage of information regarding survival rates, resurgence, vaccines, and secondary illnesses, COVID-19 and its economic impact continues to be a primary global burden. In the midst of those serious concerns, the health and life sciences (HLS) industry continues its accelerated journey of perpetual assessment and evolution. As the industry emerges from the pandemic effect, leaders are realizing that COVID-19 has provided crucial learnings to their organizations that will benefit the entire industry, according to Astound Commerce’s Tina Wilson.
Rob Steere, VP commercial strategy (CRM) for Veeva Systems, discusses ways to maximize HCP engagement in a post-COVID world.
Patient communications are no longer fit for purpose, and although Covid has brought this to the fore, the problems will continue for a long time after the vaccine roll-out if they are not resolved.
The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
PharmaLive talked to Conran Design Group Managing Director Christina Falzano about her experiences working with tech companies’ expansion into the health, wellness and pharma spaces in driving changes in the healthcare industry – especially in how they reposition post-COVID.
